(Drug-drug) interaction studies

Our group is well known for its clinical drug-drug interaction studies, mainly focused on interactions at the level of phase I metabolism (Cytochrome P450 iso-enzymes). Classic examples involve interactions between chemotherapy (i.e. irinotecan and docetaxel) and strong CYP3A inhibitors or inducers (i.e. ketoconazole, St. John’s wort, phenytoin). But also potential interactions between targeted agents and commonly used co-medication (i.e. proton-pump inhibitors and statins) have been studied within prospective studies, to explore its implications for daily clinical practice.

In line with this, two large retrospective studies were performed, that focused on intravenous and oral anti-cancer agents respectively, showing that (relevant) drug-drug interactions are unfortunately still very common. Therefore, we recently performed a large prospective trial (www.trialregister.nl, studynumber NTR3760) implementing the advice given by an expert team of clinical pharmacologists on the patients’ list of medication to decrease the number of drug-drug interactions in individual patients. Results of this trial were presented at ESMO 2014 (Madrid, Spain, September 2014) and published in Ann Oncol. 2015. May;26(5): 992-7.

Roelof ESMO 2014 resize

Roelof van Leeuwen presented his poster at ESMO 2014